Navigation Links
Fitzsimons Redevelopment Authority Names New President & CEO
Date:3/14/2012

AURORA, Colo., March 14, 2012 /PRNewswire/ -- Following an extensive national search, Fitzsimons Redevelopment Authority (FRA) has named Steve VanNurden as its new President and Chief Executive Officer, beginning in late May. The announcement is made by John M. Shaw, Chair of the FRA Board of Directors, who said: "Steve, a seasoned leader in the life science/bioscience space, comes to us from Mayo Clinic in Rochester, Minnesota."

The appointment of Mr. VanNurden is further evidence of the FRA's continued commitment to support the development of life science companies in Colorado in partnership with the State's research institutions.  He will be working with universities, local economic development agencies, state and local governments, and the bioscience industry to promote the successful development of the 180 acre Colorado Science + Technology Park, which is adjacent to the University of Colorado's Anschutz Medical Campus in Aurora.

Steve Hogan, Mayor of the City of Aurora and FRA Board member stated, "Steve is the partner we need to fulfill the promise of the bioscience industry park.  His working relationships span nationally and internationally, which will be a great advantage for us."

Steve VanNurden is currently Chair of Mayo Clinic Ventures, the invention arm for Mayo Clinic. Under Mr. VanNurden's direction, this division is responsible for patenting and commercializing Mayo's discoveries, inventions and other intellectual property. Since 1986, Mayo Clinic Ventures has successfully commercialized over 2,000 technologies and has been granted more than 1,200 patents. Under the guidance of Mr. VanNurden, Mayo's technology based ventures efforts have paid off, resulting in the formation of 45+ Mayo Clinic start-up companies.

Prior to leading Mayo Clinic Ventures, Mr. VanNurden held a variety of positions at the Mayo Clinic.  Before joining the Mayo Clinic, Mr. VanNurden's industry experience included management positions at Cargill, Inc., US Bank, and Aerodrome Airline Services, Inc. VanNurden holds degrees in Accounting and Finance and a Masters Degree in Business Administration.

About Fitzsimons Redevelopment Authority

The FRA directs the commercial developments in the Fitzsimons Life Science District, along with its partner, Forest City Science + Technology Group. Visit: http://www.fitzscience.com.


'/>"/>
SOURCE Fitzsimons Redevelopment Authority
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
2. The Fitzsimons Redevelopment Authority Selects Pharmatech Oncology as Preferred Vendor
3. Auditors Complete Kansas Bioscience Authority Forensic Audits
4. Kansas Bioscience Authority Announces FY11 Outcomes of $207 Million
5. BioNeutral Starts Commercial Deployment of Its Ygiene 206 Sterilant and Ogiene Products Within Port Authority Facilities Using T.U.C.S. Cleaning Services
6. Cord Blood America CEO and Co-Founder Matthew Schissler Named Chairman of Biotech Committee for Nevada Development Authority
7. Quest Diagnostics Increases Share Repurchase Authority By $250 Million
8. Kansas Bioscience Authority Commits $50 Million to Increase Venture Capital, Accelerate Bioscience Business Growth
9. Orcrist Bio Inc. Receives Approval from European Competent Authority to Initiate its Planned Phase I, Open-label, Single-ascending-dose, Safety Study of HYC750
10. NeoStem Expands Stem Cell Collection Center Network Into New Jersey Led by Leading Plastic Surgeon and Anti-Aging Authority
11. Orcrist Bio Inc. Files with European Competent Authority for a Phase I, Open-label, Single-ascending-dose, Safety Study of HYC750
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... Cancer experts from Austria, Hungary, Switzerland, and ... new and helpful biomarker for malignant pleural mesothelioma. Surviving Mesothelioma has just published ... , Biomarkers are components in the blood, tissue or body fluids that ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
(Date:6/24/2016)... ... 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers use ... 6000i models are higher end machines that use the more unconventional z-dimension of 20mm. ... from the bottom of the cuvette holder. , FireflySci has developed several Agilent ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
Breaking Biology Technology:
(Date:5/3/2016)... VILNIUS, Lithuania , May 3, 2016 /PRNewswire/ ... today released the MegaMatcher Automated Biometric Identification ... deployment of large-scale multi-biometric projects. MegaMatcher ABIS can ... and accuracy using any combination of fingerprint, face ... of MegaMatcher SDK and MegaMatcher ...
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
Breaking Biology News(10 mins):